Optimization of novel dual action prodrugs for treatment of osteoporosis

治疗骨质疏松症的新型双重作用前药的优化

• 批准号: 414137-2012
• 负责人: Young, Robert
• 金额: $ 11.36万
• 依托单位: Simon Fraser University
• 依托单位国家: 加拿大
• 项目类别: Collaborative Health Research Projects
• 财政年份: 2013
• 资助国家: 加拿大
• 起止时间: 2013-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=530851
• 关键词: Optimization; novel; dual; action; prodrugs

While bone loss in osteoporosis is well treated today, therapy is usually initiated only after considerable bone loss has occurred. Therefore, there is an important medical need for agents that are effective at restoring lost bone to normal levels. Bisphosphonate compounds, for example, alendronate, are regarded as standards of care for treating osteoporosis and related bone diseases; these agents target and bind to bone, and halt and partially reverse osteoporotic bone loss by inhibiting osteoclasts, specialized cells that remove bone tissue.

虽然骨质疏松症中的骨丢失今天得到了很好的治疗，但治疗通常仅在发生相当大的骨丢失后才开始。因此，对于有效地将丢失的骨恢复到正常水平的试剂存在重要的医学需求。双膦酸盐化合物，例如阿仑膦酸盐，被认为是治疗骨质疏松症和相关骨疾病的护理标准;这些药物靶向并结合骨，并通过抑制破骨细胞（去除骨组织的特化细胞）来停止和部分逆转骨质疏松性骨丢失。